The value of gene-expression profiles using micoarrays for the individualisation of adjuvant therapy after surgery for breast cancer;De waarde van genexpressieprofielen vastgesteld met microarrays voor het individualiseren van adjuvante therapie bij patiënten na chirurgische behandeling wegens mammacarcinoom

Nederlands Tijdschrift voor Geneeskunde

Volumn 149, Issue 12, 2005, Pages 618-622

  Klijn, J G M ^a   De Vries, E G E ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ACCURACY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; DNA FINGERPRINTING; DNA MICROARRAY; GENE EXPRESSION; HORMONAL THERAPY; HUMAN; PARAMETER; PREDICTION; PROGNOSIS; REVIEW; RISK ASSESSMENT;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS;

EID: 16244389291     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352:930-42.
2. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 351:1451-67.
3. The National Institutes of Health Consensus Development Conference: adjuvant therapy for breast cancer, November 1-3, Bethesda, Maryland, USA, 2000. Proceedings. J Natl Cancer Inst Monogr 2001; (30):1-152.
4. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21: 3357-65.
5. Klijn JGM, Berns PMJJ, Foekens JA. Prognostic and predictive factors and targets for therapy in breast cancer. In: Pasqualini JR, editor. Breast cancer: prognosis, treatment and prevention. New York: Marcel Dekker; 2002. p. 93-124.
6. Look MP, Putten WLJ van, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002;94:116-28.
7. Veer LJ van't, Dai H, Vijver MJ van de, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
8. Vijver MJ van de, He TO, Veer LJ van't, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
9. Wang Y, Klijn JGM, Zhang Y, Sieuwerts AM, Look MP, Yang F, et al. Gene-expression profiles to predict distant metastases of lymph-node-negative primary breast cancer. Lancet 2005;365:671-9.
10. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
11. Veer LJ van't, Rodenhuis S, Vijver MJ van de. Prognostische betekenis van het genexpressieprofiel van mammatumoren, bepaald met DNA-microarrays. Ned Tijdschr Geneeskd 2005;149:638-46.
12. Hayes DF, Bast RC, Desch CE, Fritsche Jr H, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66.
13. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 2004;4:309-14.
14. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347:1566-75.
15. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-9.
16. Jansen MPHM, Foekens JA, Staveren IL van, Dirkzwager-Kiel MM, Ritstier K, Look MP, et al. Molecular classification of tamoxifen resistant breast carcinomas by gene expression profiling. J Clin Oncol 2005;23:732-40.